Phase 2CompletedAge-related condition
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
Study of Vasomotor Symptoms in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 150 planned
- Conditions
- Vasomotor Symptoms; Endometrial Safety
- Interventions
- Raloxifene; medroxyprogesterone acetate; estrogen; 17 beta estradiol
- Ages
- adults, older adults
- Registry
- NCT00332553
Full record on ClinicalTrials.gov
From the registry
This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) compared to women treated with raloxifene HCl 60 mg alone.
Primary outcomes
- Compare the number of vasomotor symptoms at 12 weeks between those women taking the combination of raloxifene with oral estradiol versus those taking raloxifene alone.
History
Last registry update
Registered
Study completion
Started